This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The article by Drs Testa and Simonson¹ on health outcomes during improved glycemic control had some interesting, unexplained findings that raise the question of a negative impact of the trial on the placebo group. The percentage of employed patients who missed 0.5 or more days of work increased from 2.4% at baseline to 10.5% at the end of week 15 in the placebo group, compared with a decrease of 5.6% to 4.8% in the treated group. Per 500 days worked, the total days absent increased from 4.2 to 24 in the placebo group and decreased from 9.4 to 5.0 in the treated group. Bed-days (rates per 1000 person-days) had the same pattern: 921 at baseline to 1843 at the end of week 15 in the placebo group and 1653 to 1539 in the treated group. Most of the benefit attributed to improved glycemic control occurred because of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial
Marcia A. Testa and Donald C. Simonson
JAMA. 1998;280(17):1490-1496.
ABSTRACT | FULL TEXT